# Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

> **NCT06757153** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhongnan Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **DRUG:** NRG-103

## Key facts

- **NCT ID:** NCT06757153
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06757153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06757153, "Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06757153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*